Research programme: glycodesigned biotherapeutics - Glycotope

Drug Profile

Research programme: glycodesigned biotherapeutics - Glycotope

Alternative Names: GatoMab-GEX; GT-MAB 3.2-GEX; SeeloMab-GEX

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GLYCOTOPE
  • Developer Glycotope
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Jul 2017 SeeloMab-GEX™ is available for licensing as of 24 Jul 2017. http://www.glycotope.com/biopharmaceuticals-pipeline/ (Glycotope pipeline, July 2017)
  • 23 Mar 2016 Preclinical development is ongoing for cancer in Germany
  • 01 Dec 2009 Two glycooptimised biopharmaceutical products are available for partnering (http://www.glycotope.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top